Pfizer has continued its recent deal-making spree with the acquisition of a "controlling interest" in Redvax, a spin-off from Redbiotec, a privately held Swiss biopharmaceutical company.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.